Clareo Health | Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have completed an oxaliplatin-containing chemotherapy regimen post complete surgical removal of primary colon tumor no later than 6 weeks before randomization;
Have Grade ≥ 1 PSN, as defined by the NCI-CTCAE version 3.0
Have an Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2;
Blood tests within 14 days prior to randomization: (a) AST (SGOT) and ALT (SGPT) ≤2 x upper limit of normal (ULN); (b) serum creatinine ≤1.5 x ULN; (c)HbA1c ≤7%; (d) neutrophils ≥1.5x10\^9/L ; (e) platelets ≥50x10\^9/L; (f) Serum D-dimer within normal limits
You may not be if
Pre-existing peripheral neuropathy prior to treatment with oxaliplatin
Receiving any further anti-cancer treatment
History of any recent (≤1 year) thrombo-embolic events and current clinical evidence of thrombo-embolism
Unstable cardiac disease
History of significant neurological or psychiatric disorders including dementia or seizures,
Active uncontrolled infection
Active disseminated intravascular coagulation
Other serious underlying medical conditions which could impair the ability of the patient to participate in the study;
Use of antidepressant/antiepileptic medication (for the treatment of PSN), unless commenced before informed consent form signed. The addition of these medications (for the treatment of PSN) once the patient has consented is not allowed
Concurrent treatment with any other experimental drugs
Pregnant or breast-feeding women;
Women of childbearing potential must be protected by effective contraceptive methods of birth control. Post-menopausal women must have been amenorrheic for at least 12 months to be considered as having non-childbearing potential
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Those conditions should be assessed with the patient before registration in the trial.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
